Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer

Genes and Cancer

Volumn 5, Issue 7-8, 2014, Pages 273-284

  Rastogi, Anshu ^a   Tan, Shyh Han ^a   Mohamed, Ahmed A ^a   Chen, Yongmei ^a   Hu, Ying ^a   Petrovics, Gyorgy ^a   Sreenath, Taduru ^a   Kagan, Jacob ^b   Srivastava, Sudhir ^b   McLeod, David G ^a,c   Sesterhenn, Isabell A ^d   Srivastava, Shiv ^a   Dobi, Albert ^a   Srinivasan, Alagarsamy ^a  

^a Uniformed Services University of the Health Sciences   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d JOINT PATHOLOGY CENTER   (United States)

Author keywords

C MYC; Dominant negative; ERG; Prostate cancer; Splice variants

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 3; MYC PROTEIN; PHOSPHOMEVALONATE KINASE; PROSTATE CANCER ANTIGEN 3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BIMOLECULAR FLUORESCENCE COMPLEMENTATION ASSAY; CELL ASSAY; CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EXPRESSION VECTOR; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; FUSION GENE; GENE; GENE EXPRESSION; GENE FUSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TMPRSS2 ERG 3 GENE; TMPRSS2 ERG 8 GENE; TMPRSS2 ERG GENE; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 84945939780     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Albertson DG, Collins C, McCormick F and Gray JW. Chromosome aberrations in solid tumors. Nature genetics. 2003; 34(4):369-376.
2. Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A, Cao X, Lonigro RJ, Tomlins SA, Varambally S and Chinnaiyan AM. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer research. 2011; 71(16):5387-5392.
3. Kumar-Sinha C, Tomlins SA and Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nature reviews Cancer. 2008; 8(7):497-511.
4. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA and Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310(5748):644-648.
5. Rubin MA, Maher CA and Chinnaiyan AM. Common gene rearrangements in prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29(27):3659-3668.
6. Rao VN, Papas TS and Reddy ES. erg, a human ets-related gene on chromosome 21: alternative splicing, polyadenylation, and translation. Science. 1987; 237(4815):635-639.
7. Reddy ES, Rao VN and Papas TS. The erg gene: a human gene related to the ets oncogene. Proceedings of the National Academy of Sciences of the United States of America. 1987; 84(17):6131-6135.
8. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L and Nelson PS. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer research. 1999; 59(17):4180-4184.
9. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, Klaren R, Grone EF, Wiesel M, Gudemann C, Kuster J, Schott W, Staehler G, Kretzler M, Hollstein M and Grone HJ. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. The American journal of pathology. 2002; 160(6):2169-2180.
10. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, Nau M, Ravindranath L, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW and Srivastava S. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005; 24(23):3847-3852.
11. Vanaja DK, Cheville JC, Iturria SJ and Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer research. 2003; 63(14):3877-3882.
12. Zammarchi F, Boutsalis G and Cartegni L. 5' UTR control of native ERG and of Tmprss2:ERG variants activity in prostate cancer. PloS one. 2013; 8(3):e49721.
13. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, Eeles R, Martin FL, Phillips DH, Crundwell M, Christmas T, Thompson A, Fisher C, Kovacs G and Cooper CS. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007; 26(18):2667-2673.
14. Sementchenko VI, Schweinfest CW, Papas TS and Watson DK. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene. 1998; 17(22):2883-2888.
15. Rahim S and Uren A. Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer. American journal of translational research. 2013; 5(3):254-268.
16. Owczarek CM, Portbury KJ, Hardy MP, O'Leary DA, Kudoh J, Shibuya K, Shimizu N, Kola I and Hertzog PJ. Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. Gene. 2004; 324:65-77.
17. Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, Cullen J, Furusato B, Chen Y, Thangapazham RL, Mohamed A, Sun C, Sesterhenn IA, McLeod DG, Petrovics G and Srivastava S. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(15):4719-4725.
18. Wang J, Cai Y, Ren C and Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer research. 2006; 66(17):8347-8351.
19. Wang J, Cai Y, Yu W, Ren C, Spencer DM and Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer research. 2008; 68(20):8516-8524.
20. Hermans KG, Boormans JL, Gasi D, van Leenders GJ, Jenster G, Verhagen PC and Trapman J. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009; 15(20):6398-6403.
21. Mohamed AA, Tan SH, Mikhalkevich N, Ponniah S, Vasioukhin V, Bieberich CJ, Sesterhenn IA, Dobi A, Srivastava S and Sreenath TL. Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody. Journal of Cancer. 2010; 1:197-208.
22. FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL and Huntsman DG. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC cancer. 2008; 8:230.
23. Sreenath TL, Dobi A, Petrovics G and Srivastava S. Oncogenic activation of ERG: A predominant mechanism in prostate cancer. Journal of carcinogenesis. 2011; 10:37.
24. Oikawa T and Yamada T. Molecular biology of the Ets family of transcription factors. Gene. 2003; 303:11-34.
25. Rainis L, Toki T, Pimanda JE, Rosenthal E, Machol K, Strehl S, Gottgens B, Ito E and Izraeli S. The proto-oncogene ERG in megakaryoblastic leukemias. Cancer research. 2005; 65(17):7596-7602.
26. Hart AH, Corrick CM, Tymms MJ, Hertzog PJ and Kola I. Human ERG is a proto- oncogene with mitogenic and transforming activity. Oncogene. 1995; 10(7):1423-1430.
27. Sato H, Minei S, Hachiya T, Yoshida T and Takimoto Y. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients. International journal of urology : official journal of the Japanese Urological Association. 2006; 13(6):761-766.
28. Rastogi A, Tan SH, Banerjee S, Sharad S, Kagen J, Srivastava S, McLeod DG, Srivastava S. ERG monoclonal antibody (ERG MAb, 9FY) in the diagnosis and biological stratification of prostate cancer: Delineation of minimal epitope, critical residues for binding and molecular basis of specificity. Monoclon Antib Immunodiagn Immunother. 2014; In press.
29. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008; 27(40):5348-5353.
30. Venkatachari NJ, Walker LA, Tastan O, Le T, Dempsey TM, Li Y, Yanamala N, Srinivasan A, Klein-Seetharaman J, Montelaro RC and Ayyavoo V. Human immunodeficiency virus type 1 Vpr: oligomerization is an essential feature for its incorporation into virus particles. Virology journal. 2010; 7:119.
31. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA and Zhou M. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. The Prostate. 2011; 71(5):489-497.
32. Hagglof C, Hammarsten P, Stromvall K, Egevad L, Josefsson A, Stattin P, Granfors T and Bergh A. TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PloS one. 2014; 9(2):e86824.
33. Carrere S, Verger A, Flourens A, Stehelin D and Duterque-Coquillaud M. Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains. Oncogene. 1998; 16(25):3261-3268.
34. De Val S, Anderson JP, Heidt AB, Khiem D, Xu SM and Black BL. Mef2c is activated directly by Ets transcription factors through an evolutionarily conserved endothelial cell-specific enhancer. Developmental biology. 2004; 275(2):424-434.
35. Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S and Sesterhenn IA. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate cancer and prostatic diseases. 2010; 13(3):228- 237.
36. Miettinen M, Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S and Sesterhenn I. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. The American journal of surgical pathology. 2011; 35(3):432-441.
37. Li R, Pei H and Watson DK. Regulation of Ets function by protein - protein interactions. Oncogene. 2000; 19(55):6514-6523.
38. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S and Petrovics G. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate cancer and prostatic diseases. 2010; 13(4):311-315.
39. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, Gerald WL and Sawyers CL. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature genetics. 2009; 41(5):524-526.
40. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA and Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(30):12465-12470.